Selenium-binding protein 1 (SELENBP1) has been associated with several cancers, although its exact role is unknown. We show that SELENBP1 is a methanethiol oxidase (MTO), related to the MTO in methylotrophic bacteria, that converts methanethiol to H 2 O 2 , formaldehyde, and H 2 S, an activity not previously known to exist in humans. We identified mutations in SELENBP1 in five patients with cabbage-like breath odor. The malodor was attributable to high levels of methanethiol and dimethylsulfide, the main odorous compounds in their breath. Elevated urinary excretion of dimethylsulfoxide was associated with MTO deficiency. Patient fibroblasts had low SELENBP1 protein levels and were deficient in MTO enzymatic activity; these effects were reversed by lentivirus-mediated expression of wild-type SELENBP1. Selenbp1-knockout mice showed biochemical characteristics similar to those in humans. Our data reveal a potentially frequent inborn error of metabolism that results from MTO deficiency and leads to a malodor syndrome.
T he volatile sulfur-containing compounds hydrogen sulfide (H 2 S), methanethiol (MT, CH 3 -SH) and dimethylsulfide (DMS, CH 3 -S-CH 3 ) have been identified as the main contributors to halitosis or bad breath 1 . The origin of halitosis can be intra-or extraoral [2] [3] [4] . Intraoral halitosis, the most common form, is usually caused by methanethiol and H 2 S produced by Gramnegative bacteria located on the dorsum of the tongue or in gingival and periodontal crevices. Extraoral halitosis has an estimated prevalence of 0.5-3% in the general population 2 , and its origin is not completely understood. Extraoral bad breath can be caused by conditions affecting the nose, sinuses, tonsils, and esophagus, but in some individuals, the extraoral halitosis is bloodborne 3 . In bloodborne halitosis, malodorant compounds, most commonly DMS, are carried to the lungs, where they enter the breath 3 . The DMS concentrations in oral and nasal breath have been found to be sixfold higher in people with extraoral halitosis than in controls 2 . The cause of elevated DMS levels in these individuals is unknown. DMS is produced from methanethiol through methylation. Both DMS and methanethiol result from the complex microbiome and mammalian co-metabolism of volatile sulfur compounds 5, 6 (Fig. 1) . Under physiological conditions, methanethiol has three sources in the human body 7, 8 : synthesis from sulfur-containing amino acids by intestinal bacteria; synthesis in intestinal cells through methylation of H 2 S by thiol S-methyltransferase; and synthesis from methionine through the transamination pathway in human endogenous metabolism. Under pathological conditions, increased levels of DMS can lead to high concentrations of dimethylsulfoxide (DMSO) and dimethylsulfone (DMSO 2 ) 9 . The enzymes involved in these conversions are largely unknown, and gut bacteria are also thought to contribute to the conversion process 5, 6 . Interestingly, people with cancer produce methanethiol and DMS as prominent volatile organic compounds 10, 11 . DMS is produced in substantial amounts by lung and liver cancer cell lines 10, 12 and has been found in lung tumor tissue 13 .
A methanethiol oxidase (MTO) has been purified from the Hyphomicrobium strain VS 14, 15 . This enzyme has 26% similarity at the amino acid level to human SELENBP1, a protein that can bind selenium but whose function is unknown [16] [17] [18] . Low expression of the human gene has been found in several tumors, and a tumorsuppressor function has been suggested for this gene [19] [20] [21] . We hypothesized that mutations in SELENBP1 might cause extraoral halitosis. Through studying five patients with extraoral halitosis caused by elevated levels of DMS in the blood, we identified SELENBP1 as the human MTO catalyzing the conversion of methanethiol into formaldehyde, H 2 S, and hydrogen peroxide (H 2 O 2 ). Mutations in SELENBP1 cause extraoral halitosis and define a novel inborn error of metabolism.
Mutations in SELENBP1, encoding a novel human methanethiol oxidase, cause extraoral halitosis
Breath and body-fluid analyses. For breath and body-fluid analyses, we used complementary methods (NMR spectroscopy and gas chromatography) ( Table 1 ). Because of the malodorous body fluid, NMR spectroscopy was requested for the index patients in the three families. NMR showed the presence of elevated concentrations of DMSO and DMSO 2 in the body fluids (Fig. 2b,c) .
Using gas chromatography with a sulfur-specific detector, we detected high concentrations of an additional sulfur-containing compound, DMS, in the affected individuals (Table 1b) . Elevated blood DMS concentrations have been described in people with extraoral halitosis 3, 4 . Elevated concentrations of DMSO 2 , an oxidation product of DMS, have been observed in the blood of individuals with methionine adenosyltransferase deficiency 9 . DMSO 2 also occurs in cerebrospinal fluid after intake of DMSO 2 as a dietary supplement 22 . Additional investigation of breath samples from AII-3 and CII-2 identified elevated levels of a fourth sulfur-containing compound, methanethiol. The methanethiol concentration in the breath of these patients was ten times higher than the highest values in control individuals and unaffected family members. Specialized dental clinics may use portable gas chromatography to detect this specific form of halitosis (breath analysis of CII-2 in Supplementary  Fig. 1 ). We detected elevated methanethiol levels in the urine in some of our patient samples. Because methanethiol is highly volatile and reactive, reproducible quantification of urinary methanethiol was not possible.
Patient BII-2 was treated for 5 d with the antibiotic metronidazole (500 mg oral; three times per day), after which the concentration of DMS in the breath decreased to just above the detection limit. DMS and methanethiol in the urine decreased to 65% after 5 d of metronidazole administration. After cessation of treatment, the DMS levels in the breath and urine returned to pretreatment values. In patient AII-3, a methionine-loading trial was performed. The initial levels of 18 and 129 μ mol per mmol creatinine for DMSO and DMSO 2 , respectively, rose to 67 and 178 μ mol per mmol creatinine, respectively, at 12 h after loading. At 20 h, the levels were still elevated (48 and 152 μ mol per mmol creatinine). These data are in line with a major contribution of the microbiome and of methionine metabolism to the breath-and body-fluid concentrations of methanethiol, DMS, and its oxidation products DMSO and DMSO 2 in affected individuals.
Mutational analysis of SELENBP1. On the basis of the observed accumulation of sulfur-containing compounds in our patients, we postulated a pathway defect that resulted in DMS accumulation. We hypothesized that defects in methanethiol oxidation would lead to higher levels of methanethiol and to an alternative metabolism resulting in higher DMS, DMSO, and DMSO 2 levels ( Fig. 1 ). Methanethiol-degrading enzymes are not known in humans, but methanethiol oxidases (EC 1.8.3.4) have been purified from Hyphomicrobium strain EG 23 and Thiobacillus thioparus TK-m 24 . Recently the gene mtoX, encoding a protein with MTO activity, has been found in Hyphomicrobium strain VS 15 . BLAST searching the human protein database on the basis of the Hyphomicrobium strain VS MTO amino acid sequence yielded a single hit, seleniumbinding protein 1 (SELENBP1/SBP1/hSBP/SBP56), with a sequence identity of 26% and sequence similarity of 54% ( Supplementary  Fig. 2 ). SELENBP1, the gene encoding this candidate protein, is located on chromosome 1 (151364302-151372734), within a linkage interval with a logarithm-of-the-odds score of 1.8 found in family A. The protein is well conserved among the three domains of life (phylogenetic tree for humans, bacteria, and archaea in Fig. 3a ). Subsequent SELENBP1 Sanger sequencing showed four different biallelic mutations in our five patients ( Table 2) . Segregation with the malodor was confirmed in the three pedigrees.
Pathogenicity of SELENBP1 mutations. The four mutations were predicted to be pathogenic by the algorithms Align GVGD, SIFT, MutationTaster, and PolyPhen-2 ( Table 2 ). As calculated with the Combined Annotation Dependent Depletion (CADD) tool, the mutations ranked in the top 1% (C score ≥ 20) or the top 0.1% (C score ≥ 30) of most deleterious mutations ( Table 2 ). We modeled the human SELENBP1 protein containing the two family C alterations on the X-ray structure of the hypothetical seleniumbinding protein from the archaeon Sulfolobus tokodaii (PDB 2ECE) ( Fig. 3b ,c). p.Gly225Trp is likely to be incompatible with the original structure, because Gly225, without a side chain, is replaced by a bulky tryptophan. Moreover, Gly225 is conserved in methanethiol oxidases and putative selenium-binding proteins from all domains of life. For the c.985 C> T mutation, changing His329 to tyrosine, the pathogenicity was less obvious from the structural analysis. The mutant residue is only slightly larger and does not appear to collide with adjacent side chains, but His329 is conserved in eukaryotic orthologs and is close to a fully conserved region ( Fig. 3d ).
Diagnostic assay for MTO enzyme deficiency. We developed a functional MTO enzymatic assay to demonstrate that SELENBP1 has MTO activity, to evaluate its biochemical characteristics, and to establish the residual activity in affected individuals (Methods and Supplementary Fig. 3 ). MTO activity in different blood fractions of control individuals showed relatively high activity in erythrocyte extracts but with a broad range (0.04-6.1 nmol µ l −1 h −1 , mean 1.4, median 0.63; n = 30; Fig. 4a and full-length blots in Supplementary Data 1). MTO activity was low in leucocytes from control individuals and was scarcely detectable in plasma (not shown). Erythrocytes from patients AII-3 and CII-2 had very low MTO activity (0.017 and 0.022 nmol µ l −1 h −1 ), in line with a deficiency of the enzyme, thus supporting a functional role of SELENBP1 protein as a methanethiol oxidase. SELENBP1 protein and activity in cell lines. SELENBP1 mRNA was ubiquitously expressed. The highest RNA levels were found in adult tissues, mainly kidney, duodenum, liver, lung, and brain tissues ( Fig. 4b ).
SELENBP1 has been described as a tumor marker with low expression in certain cancers and tumor cell lines 20, 21 . To correlate the protein expression levels with our biochemical results, we analyzed colon cancer lines with previously documented high (HT29 cells) or low (SW480 cells) SELENBP1 expression 25 . Western blot analysis of these cell lines ( Fig. 4c ) was consistent with published results. The MTO enzymatic activity was high in HT29 cells (4.2 nmol mg protein −1 h −1 ) and undetectable in SW480 cells, in line with expression data from the literature and corresponding with the western blot results.
Fibroblast lines from patients (AII-3 and CII-2) had significantly lower SELENBP1 protein levels than did control cells (Fig. 4d ). The MTO enzyme activity in the patient cells was not detectable (whereas that in controls was 2.6-6.6 nmol mg protein −1 h −1 ). We demonstrated that the MTO enzyme activity in control fibroblasts, ) ranges were obtained from 20 control individuals sampled at arbitrary times throughout the day (given as mean ± 1 s.d. and range). The values from individuals fluctuated during the day (up to a factor of 10); these values are all included in the reference range. The DMS reference range corresponds to the range previously published 2,53 . ND, not determined; p.p.b., parts per billion. Bottom, DMS, DMSO, and DMSO 2 levels in body fluids of the affected individuals and controls. Reference ranges for DMSO 2 have been previously described 9 . DMS was measured in blood; DMSO and DMSO 2 were measured in plasma. Cr, creatinine; CSF, cerebrospinal fluid. a Range of measurements taken at different time points during the day.
HT29 cells, and control erythrocytes was dependent on the presence of oxygen ( Supplementary Fig. 3b ,c) and that the molar amount of H 2 S formed was equal to the amount of converted substrate (MT).
SELENBP1 has a nanomolar-range K m for MT. For accurate kinetic analysis, we supplemented the reaction mixture with bovine serum albumin (BSA; 0.3 mg/ml), which stabilizes MTO at low protein concentrations. A kinetic analysis with erythrocytes was performed by varying the initial methanethiol concentrations and measuring the initial reaction rates ( Supplementary Fig. 3d 52 ). b, The SELENBP1 sequence was modeled on the X-ray structure of the hypothetical selenium-binding protein from S. tokodaii (PDB 2ECE). The protein forms a typical WD40 fold. The positions of the alterations p.Gly225Trp (right) and p.His329Tyr (left) are indicated in red. c, Detail of the amino acid changes in family C. Green, original residue; red, altered residue in the patients. d, Alignments of the regions of SELENBP1 from multiple species, indicating the conserved residues altered in family C. The amino acid numbering is according to the human sequence. Asterisks, fully conserved residues; colons, conservation of amino acids with highly similar properties; periods, conservation of amino acids with weakly similar properties. Frequency of SELENBP1 mutations. Using data from the Exome Aggregation Consortium (ExAC) browser and a local dataset of 15,000 exomes, we found evidence of a possible frequency of biallelic pathogenic SELENBP1 mutations of approximately 1:90,000, corresponding to a carrier frequency of 1 per 300 individuals (Supplementary Note and Supplementary Table 1 ). According to these data, MTO deficiency may be a frequent inborn error of metabolism. The frequency of extraoral halitosis has previously been estimated 2 to be between 0.25% and 1.5%, thus indicating that biallelic mutations in SELENBP1 may explain a minority of extraoral halitosis cases.
Lentiviral complementation analysis.
To further substantiate that MTO activity depends on the presence of SELENBP1, we performed a lentiviral complementation experiment in a patient fibroblast cell line (Fig. 4f ). The cell line from patient AII-3 and a control fibroblast line were lentivirally transduced with either a control virus for expression of V5-epitope-tagged green fluorescent protein (GFP) or a virus for expression of V5-tagged wild-type SELENBP1. The exogenous protein was expressed in the nucleus but primarily in the cytoplasm. The cytoplasmic staining was not uniform but appeared to follow internal filamentous structures ( Supplementary Fig. 4 ), as seen in previous studies 21, 26, 27 .
Subsequently, we analyzed MTO activity in cell lines stably expressing MTO. The MTO activity in patient fibroblasts expressing only GFP protein and in the nontransduced cells was undetectable. In addition, little or no SELENBP1 protein was seen in western blots. Introducing exogenous SELENBP1-V5 protein in patient fibroblasts resulted in reexpression of SELENBP1, as detected with the specific antiserum as well as with an anti-V5-tag antiserum. Moreover, the MTO enzyme activity increased from undetectable levels to 55% those of the control cell line.
SELENBP1-knockout mice. A knockout (KO) mouse line was previously created by the Knockout Mouse Program Project (KOMP)
at the University of California, Davis. This mouse, expressing a 'KO first' allele of Selenbp1 tm1b(KOMP)Wtsi , had no apparent phenotypic changes. MTO enzyme activity and metabolite concentrations were measured in KO mice, heterozygous carriers and wild-type mice. The MTO activity in the erythrocytes of wild-type mice was 1.8 nmol µ l −1 h −1 , representing the same order of magnitude as that in human erythrocytes. The MTO activity in mouse erythrocytes was also strictly dependent on oxygen and yielded stoichiometric amounts of sulfide (data not shown).
The MTO activity in KO mouse erythrocytes was deficient (at the limit of detection at 0.05 nmol µ l −1 h −1 ), whereas heterozygous mice had an intermediate activity (0.8 nmol µ l −1 h −1 ; Fig. 5a ). MTO enzyme activity was measured in four different tissues (Fig. 5b ). The highest activity in wild-type animals was found in the liver. The activity in liver and kidney was more than tenfold higher than that in the muscle and brain. In KO animals, the residual activity in all tissues was < 6% that in wild-type animals, thus illustrating the enzyme deficiency. The affinity constants of MTO from mouse tissue extracts (liver shown in Supplementary Fig. 3g ) and mouse erythrocytes (data not shown) were 4-6 nM, values similar to the low apparent K m in human erythrocytes and HT29 colon cells ( Supplementary Fig. 3e ,f).
Because the loss of MTO activity in the patients resulted in accumulation of DMS and DMSO 2 we also measured these products in the plasma of the mice. Because methanethiol levels were expected to be much lower than those of DMS in the blood and because of the highly volatile nature of the compound, we did not quantify methanethiol in the small amounts of plasma available. The DMS levels in the plasma of KO mice were significantly higher than the control levels ( Fig. 5c ). Interestingly, the DMS levels were also moderately elevated in the plasma in the heterozygous mice, thus suggesting a mild biochemical phenotype of the gene defect in the heterozygous mice, such that that the lower MTO activity cannot accommodate the usual flux through this enzymatic reaction. An accumulation of DMSO 2 was observed in the plasma in the KO mice but was not detectable in plasma from both the wildtype mice ( Fig. 5d ,e; 36 µ M) and the heterozygous mice (data not shown). Overall, the biochemical characteristics of the patients were mimicked in the KO mouse model.
Discussion
We described a group of individuals with extraoral halitosis, in whom all known causes of extraoral halitosis, fetor hepaticus caused by liver cirrhosis 28 , medicine use, and cysteamine treatment in cystinosis 29 were excluded. In addition, methionine adenosyltransferase deficiency 9, 30 and trimethylaminuria 3 were excluded. The patients exhibited elevated concentrations of four sulfur-containing metabolites in their body fluids and breath. Methanethiol and DMS, which have a high odor index, were responsible for the malodor. In agreement with our findings, urinary excretion of DMSO 2 is a diagnostic characteristic of this form of extraoral halitosis. We hypothesized that the metabolic defects in our patients might be related to impaired methanethiol metabolism. Methanethiol is known to be produced in substantial amounts by gut bacteria and has been reported to be oxidized to H 2 S (ref. 7 ); however, the methanethiol oxidase enzyme responsible for this oxidation had not been identified. Our data indicated that SELENBP1 is the human MT-oxidase. Moreover, we found that biallelic mutations in SELENBP1 are the underlying cause of a novel autosomal-recessive malodor syndrome. Mutations in SELENBP1 had not previously been implicated in a genetic disorder. However, elevated expression of SELENBP1 has been reported in the blood and dorsolateral prefrontal cortex in people with schizophrenia [31] [32] [33] .
The malodor was the unifying clinical feature in the affected individuals and was the only clinical feature in both affected individuals in family C. There is consanguinity in families A and B. The additional neurological signs and symptoms of patients AII-3 and BII-2 but not AII-2 may have had other causes. Whole-exome analysis in family A identified pathogenic mutations in THAP4 as a potential cause of the neurological features in AII-3 (detailed patient description in Supplementary Note; Supplementary Fig. 5 ). Our data thus suggest that defects in SELENBP1 may cause a malodor syndrome without neurological sequelae. Further studies are required to elucidate the full phenotypic consequences of SELENBP1 defects. A previous study 34 has described a specialized detoxification system in colonic mucosa that converts methanethiol into appreciable amounts of H 2 S. Defective mucosal detoxification of methanethiol may lead to ulcerative colitis 34 and hence may potentially be linked with the strong familial clustering of ulcerative colitis. Our findings suggest that investigating the potential involvement of SELENBP1 in ulcerative colitis may be worthwhile. SELENBP1 was first cloned by Chang 35 on the basis of its homology to the mouse selenium-binding protein (mSBP56) 17, 18 . Binding of selenite by SELENBP1 has been suggested to occur through Cys57 (ref. 16 ). The bacterial MTOs do not have cysteine at position 57 or nearby. Therefore, selenium binding does not appear to be essential for the MTO enzyme activity of SELENBP1. Selenite binding has been found to be essential for specific interaction of SELENBP1 with von Hippel-Lindau protein-interacting deubiquitinating enzyme 1 (ref. 26 ). SELENBP1 was not previously known to possess enzymatic activity 26 . In control human fibroblasts and erythrocytes incubated with the MTO substrate MT, we observed a rapid conversion of MT over time and measured stoichiometric amounts of the H 2 S formed.
The enzymatic activity was strictly dependent on the presence of oxygen. We based the presumed reaction formula (Fig. 1) on our results and on reported data for the homologous Hyphomicrobium strain VS enzyme, for which H 2 O 2 and formaldehyde are confirmed reaction products 15 . The apparent K m of the human MTO toward methanethiol was very low, at 4.8 nM. According to the BRENDA enzyme database (URLs), very few enzymes have such a low K m value. The formation of DMS from methanethiol is normally of minor importance (an estimated 1% of methanethiol is converted into DMS in control individuals 7 ). The high flux through the MTO reaction was apparent in our patients and in the KO-mouse model. In the deficiency state, an alternative metabolic pathway produced substantial amounts of DMS, DMSO, and DMSO 2 in the body fluids of the affected individuals. This result underscores the relevance of the MTO enzyme reaction in human metabolism.
Deficiencies in MTO activity may have metabolic consequences, such as toxicity effects due to accumulating sulfur compounds. Data on the toxicity of methanethiol, DMS, and DMSO are anecdotal, and only little is known about the low-dose toxicity of these compounds (ref. 36 37 . H 2 S is a gaseous signaling molecule, a gasotransmitter, like nitric oxide and carbon monoxide 38 . At low concentrations, it acts as a mitochondrial electron donor, thus stimulating electron transport in mammalian cells 5 . The general effect of H 2 S is cytoprotective 5 , and H 2 S therapy for several disorders aims at vasodilatation, antioxidant upregulation, inflammation inhibition, and activation of antiapoptotic pathways [38] [39] [40] . At high concentrations, H 2 S is toxic through its known inhibition of respiratory-chain complex IV. In view of these data from the literature, we cannot exclude the possibility that toxic effects of accumulating sulfur compounds or the lack of H 2 O 2 or the gasotransmitter H 2 S may cause other clinical signs and symptoms beyond malodor in people with SELENBP1 mutations. The low apparent K m of MTO may be important in preventing methanethiol toxicity but also may have a role in the gasotransmitterproducing system that operates at the nanomolar level. Three enzymes in human metabolism are known to produce H 2 S: cystathionine β -synthase (CBS), cystathionine β -lyase (CSE or CGL) and 3-mercapto-pyruvate sulfur transferase (3MST) 41 . Our data showed that the MTO encoded by SELENBP1 is a fourth human H 2 S-producing enzyme. The degree to which SELENBP1 contributes to total H 2 S production is currently unknown. The function of SELENBP1 might possibly be keeping the breath methanethiol concentration low, thus enabling the human nose to detect foul smells from environmental volatile sulfur compounds. The human nose is very sensitive to methanethiol and DMS, both of which have very high odor-index values 3 . The sensitivity toward sulfur-containing compounds is evolutionarily beneficial, because these compounds often represent 'danger' in the form of decaying food sources. The low apparent K m of MTO is essential in keeping the methanethiol concentration in the body below the odor threshold level.
The presence of MTO activity in erythrocytes is rather surprising, because red blood cells have few functions other than transporting oxygen. The presence of SELENBP1 protein as one of the major nonheme proteins in these cells has previously been described in naked mole rats 42 and in humans 33, 43 . In addition, one of the other known H 2 S-producing enzymes, 3MST, has been found in erythrocytes. Local H 2 S production in the bloodstream may be important for vasodilatation 44, 45 . A second H 2 S-producing enzyme in red blood cells underpins the importance of this metabolite in these cells or in the function of erythrocytes in the delivery of H 2 S cargo. It remains to be established which of these two enzymes has the more important contribution to H 2 S formation in the blood. We observed no indications of vascular problems in our patients with MTO mutations, but further investigations are required.
SELENBP1 is a possible biomarker for disease progression in several cancers, such as breast, renal cell, and colorectal cancers 46 . Notably, we observed no indication that our patients with SELENBP1 mutations had an increased risk of developing cancer. Low SELENBP1 mRNA or protein levels are associated with poor clinical cancer prognoses 46 , thus suggesting that SELENBP1 might be a tumor suppressor 20 . In support of a tumor-suppressor role and the MTO enzymatic activity of SELENBP1, A549 lung cancer and HepG2 liver cancer cell lines produce DMS and other volatile sulfur compounds 10, 12, 47 . DMS and methanethiol have been detected in the breath of people with lung cancer 10, 11 . DMS, which is normally absent in lung tissue, has been detected in lung tumor tissue 13 . Methanethiol has been found to be elevated in flatus samples from people with colon cancer 10 . Interestingly, prevention of diffusion of sulfur-containing gases from the tumor in an animal model has been found to significantly decrease the tumor proliferation rate 11 . The mechanism of SELENBP1 tumor suppression is largely unknown 25 ; however, the interaction of SELENBP1 with von Hippel-Lindau protein-interacting deubiquitinating enzyme 1, which is involved in cancer suppression, may play a role 26 . SELENBP1's interaction with GPX1 (glutathione peroxidase 1), another selenocysteinecontaining protein, may also be relevant 48 . Both proteins are present in erythrocytes. GPX1 is a potent antioxidant enzyme involved in counteracting oxidative stress by reducing peroxide to water and thereby limiting its destructive effects 49 . Several cancers have been described to have low GPX1 expression (reviewed in ref. 50 ). Beyond their tight physical interaction, SELENBP1 and GPX1 have complex regulatory effects on each other 48 . Our finding that SELENBP1 is a human MTO that produces H 2 O 2 , which is enzymatically converted by GPX1, may shed new light on the interactions between SELENBP1 and GPX1. Deregulation of either enzyme may cause an imbalance in local H 2 O 2 concentrations. The H 2 O 2 concentration must be controlled because of its bivalent roles in both oxidative damage and cellular signaling 37 . The function of SELENBP1 in sulfur metabolism sheds new light on the tumor-suppression mechanism and the role of the local concentrations of methanethiol, DMS, and H 2 S in this process. Notably, dogs can smell the presence of some tumors in humans 51 . On the basis of our data, we speculate that methanethiol and DMS might be the compounds detected by the dogs.
In summary, the putative tumor-suppressor role of SELENBP1 and the presence of DMS in tumors are consistent with the enzymatic function of SELENBP1 as a human methanethiol oxidase.
In conclusion, our experiments identified a novel enzyme activity of a human methanethiol oxidase. The enzyme is encoded by SELENBP1. SELENBP1 mutations cause extraoral halitosis, an autosomal-recessive syndrome in which malodor results from accumulation of sulfur-containing metabolites. Theoretically, this syndrome may be an inborn error of metabolism that may be treatable through dietary measures. SELENBP1 has been studied as a biomarker for several cancers. The finding that SELENBP1 has an enzymatic role in sulfur metabolism and influences the concentrations of the biologically active molecules H 2 O 2 and H 2 S may provide the cancer field with new clues and targets for future investigation.
URLs. BRENDA, https://www.brenda-enzymes.org/; CADD, http://cadd.gs.washington.edu/; ExAC, http://exac.broadinstitute. org/; KOMP, https://www.komp.org/; Molecular Evolutionary Genetics Analysis (MEGA6), http://www.megasoftware.net/; Protein Information Resource (PIR), http://pir.georgetown.edu/ pirwww/search/; Persistence of Vision Raytracer (PovRay), http:// www.povray.org/; TOXNET, https://toxnet.nlm.nih.gov/; WHAT IF, http://swift.cmbi.ru.nl/whatif/; Yet Another Scientific Artificial Reality Application (YASARA), http://www.yasara.org/.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-017-0006-7.
Subjects and data. This study adhered to the Declaration of Helsinki, and written informed consent was obtained from each individual. A full description of the patients can be found in the Supplementary Note.
Statistics, body fluids, cells and animal model. Statistical analysis was performed in GraphPad Prism 5.
Human blood cells were obtained from anonymized samples from the Radboud University Medical Center. White blood cells were obtained after dextran gradient sedimentation. The leucocyte fraction contained lymphocytes and granulocytes. Erythrocytes were obtained after slow centrifugation (600 g) of heparinized blood. Plasma and white blood cells were removed, and the erythrocytes were extensively washed with PBS before being snap frozen as pellets. The erythrocyte extracts had a protein concentration between 240 and 280 mg/ml. Anonymized plasma was obtained from healthy volunteers after informed consent was obtained.
C57BL/6N-Selenbp1 tm1b(KOMP)Wtsi /Mbp KO mice (Mus musculus) were genetically engineered to delete the critical coding region and create a homozygous null mutation of the Selenbp1 gene in all somatic and germline tissues. This KO model was generated as part of the US National Institutes of Health Knockout Mouse Production and Phenotyping Project. The KO-mouse line was created by KOMP at UC Davis in full compliance with all applicable laws and regulations for the KOMP program. Animal care and use was in accordance with guidelines in the eighth revision of the Guide for the Care and Use of Laboratory Animals. The care, use, and disposition of all mice used in this study were reviewed and approved by the Institutional Animal Care and Use Committee of the University of California at Davis. This study used both male and female homozygous mutant mice ranging from 8 to 18 weeks of age for urine collections, and from 11 to 20 weeks of age for endpoint blood and tissue collection. Mouse plasma samples, washed erythrocytes (prepared in the same manner as the human erythrocytes) and snap-frozen tissue samples on dry ice were sent by courier to Nijmegen, the Netherlands. For the animal studies, no randomization was used, and no animals were excluded from this study. The investigators were not blinded to the group allocation of the animal samples.
NMR spectroscopy of body fluids. DMSO and DMSO 2 in human plasma, urine and CSF were measured through proton NMR spectroscopy essentially as previously described for plasma, CSF 9, 54, 55 , and urine 56 . The lower limit of detection for DMSO and DMSO 2 was 1 µ M. Plasma samples from mice were diluted (300 µ l plasma with 500 µ l H 2 O) before deproteinization with a 10-kDa filter. Proton NMR spectra from these samples were obtained at pH 2.5 on a 500 MHz Bruker spectrometer using the Bruker noesygppr1d pulse program and 256 scans. Plasma NMR spectra were obtained from homozygous, heterozygous and wild-type mice (n = 2 each).
GC analysis of H 2 S, MT, and DMS.
Analysis of methanethiol for comparison of fibroblast MTO activity was done with a Chrompack CP9001 GC equipped with a sulfur-specific flame photometric detector (FPD) and a 2-m glass column (4-mm ID) packed with Carbopack B HT, as previously described 57 . In addition, an Agilent 7890B gas chromatograph was used, with an FPD detector with a lower detection limit of 0.05 pmol. This setup allowed us to study the methanethiol kinetics of MTO in the low-nanomolar range. This GC had the same Carbopack B HT100 column fitted to the capillary inlet of the FPD detector (set at 200 °C). The empty part of the inlet side of the column was extended into the heated GC inlet (150 °C) up to the septum to avoid any contact of sample gas with metal parts, because methanethiol and other volatile sulfur-containing compound are notorious for their stickiness to metals. For both GCs, the carrier gas was nitrogen (80 ml/min). For MTO enzyme activity assays in which both hydrogen sulfide and methanethiol were measured, the column was set at 100 °C. For the higher sensitivity desired for analysis of MTO kinetics when sulfide was trapped, the temperature was set at 130 °C. For methanethiol and DMS analysis in breath samples, the initial column temperature was set at 100 °C and after 0.5 min was increased to 140 °C, thus resulting in retention times of 0.6 min for H 2 S, 1.4 min for methanethiol, and 6 min for DMS, respectively.
Analysis of methanethiol and DMS in breath.
Breath samples were collected in 3-l Tedlar bags (SKC, Procare) via a tube (4-mm ID). The end of this tube was pierced through a 12-mm rubber stopper. The stopper was pressed against one nostril while the other nostril was kept closed. The bag was filled in two to four increments after a relatively deep breath was taken through the nose. Each increment lasted 5-10 s. For DMS analysis, 3-ml subsamples were taken from the bag and injected into the GC (lower limit of detection 1 p.p.b.). For methanethiol analysis, 400-ml subsamples were concentrated in a Tenax tube (13 cm, 3-mm ID) that was kept in dry ice (10-min precooling). Approximately 1.5 cm of the Tenax tube protruded above the dry-ice pellets and was insulated by polystyrene, to prevent methanethiol absorption at the top of the Tenax tube. The breath subsamples were pushed manually over the Tenax tube with a 100-ml glass syringe (with a Teflon plunger tip) at a rate of 5 ml/s. To trap water from the breath samples, a tube (8 cm, 4-mm ID) filled with CaCl 2 ·2H 2 O was fitted in between the syringe and the Tenax tube. The end of the Tenax tube was extended with a 40-cm empty section that was coiled and protruded above the dry ice. This section acted as a reservoir for nitrogen gas that was passed over the Tenax tube after the samples (15 s at 200 ml/min). To desorb the trapped methanethiol, a 3-ml plastic syringe (Braun Injekt, fully polypropylene/polyethylene with no rubber plunger tip) was connected to the inlet of the Tenax tube, which was subsequently removed from the dry ice and quickly submerged completely in a hot-water bath (95 °C). After 20 s in the water bath, the 3-ml syringe was filled quickly, thus passing the hot nitrogen from the gas reservoir over the Tenax tube. The contents of the 3-ml syringe were then injected into the Agilent 7890B gas chromatograph (described above). The methanethiol recovery of the Tenax trapping/desorbing method described here was ~60%. Calibration of methanethiol for this method was done by injecting increasing amounts from a methanethiol stock into a 15-l Tedlar bag that was filled with 10 l of clean air. The lower limit of detection for methanethiol in this method was five parts per 10 12 (p.p.t.). The loss of methanethiol in Tedlar bags at room temperature was estimated to be 10-25% after 1 d and was verified for each bag used. Analysis was performed within 8 h (patient CII-2, loss < 10%) and 24 h (patient AII-3, loss < 10%). The Tenax trapping method was similar to that described previously by Tangerman 58 , who used liquid nitrogen for cooling. The method has drawbacks of some inherent inaccuracies and difficulties. Methanethiol adsorbs to the Teflon parts of the 100-ml glass syringe. Because the same syringe was used throughout, cleaning was critical between samples, whose methanethiol concentration differed by up to a factor of 30. Cleaning of the Tedlar bags used for collecting breath samples was similarly crucial. Variation in the gas flow rate from the syringe during concentration of the methanethiol in the Tenax tube may cause differences in the Tenax zone (both width and position) that is loaded with methanethiol, thus influencing the desorption behavior. Moreover, there is limited reproducibility in the positions of the Tenax tube in the dry-ice pellets during loading and in the hot-water bath for desorption of the Tenax tube, as well as the gas flow rate during manual desorption of methanethiol by the 3-ml syringe. However, the reproducibility of duplicate samples from the same bag was fairly good, with differences less than 20%. Differences were occasionally higher, up to 50%, only for the low-p.p.t. (parts per trillion) values close to detection level.
Cell culture. Fibroblasts were cultured through standard procedures at 37 °C with 5% CO 2 in M199 medium (Gibco, Life Technologies) supplemented with 10% FCS (GE Healthcare) and 100 U/ml or 100 µ g/ml of penicillin/streptomycin (P/S) (Gibco). All cell lines were routinely tested for mycoplasma infection and were used in experiments only when negative.
Cell lysates and western blot analysis. For protein expression analysis by SDS-PAGE and western blot analysis, fibroblasts and colon cancer cell extracts
were made by extraction in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 10% glycerol, and 1% Triton X-100) for 10 min on ice and subsequent clearance (10 min, 13,000 g). Protein concentrations were measured with a Micro BCA protein assay kit (Thermo Scientific) with BSA as a standard. Forty micrograms of total extract was separated on 10% SDS-PAGE gels. The following antisera were used: anti-V5 (Invitrogen R960 mouse monoclonal), anti-SELENBP1 (Sigma SAB2108611 affinity-purified rabbit polyclonal), and anti-β -actin (Novus Biologicals AC-15 mouse monoclonal). Western blot analysis was performed two or three times for each experiment. Representative results are shown in the figures. For the MTO assay, the snap-frozen fibroblast and erythrocyte pellets that had been stored at -80 °C were resuspended in PBS and homogenized by extensive pipetting. White blood cells were also resuspended in PBS and homogenized by sonication. The protein concentrations of the resulting homogenates ranged from 1 to 4 mg/ml, as measured with a Bio-Rad Protein Assay kit with BSA as a standard.
Tissue extracts. Tissue samples (snap frozen and stored at -80 °C) were thawed on ice, finely chopped, and homogenized in Tris buffer with a tight-fitting potter (10 mM Tris-HCl, pH 7.4, 250 mM sucrose, 2 mM K + -EDTA, 5 × 10 4 U heparin/l). The homogenate was centrifuged (10 min, 600 g) and stored in aliquots at -80 °C.
Molecular genetic analysis.
Total DNA was extracted with a QIAamp DNA kit (Qiagen), and all exons and relevant splice sites were PCR amplified with primers containing the M13 forward or reverse sequence fused to a specific sequence and sequenced with M13 primers. Primer sequences are available upon request. Mutations were analyzed with Alamut version 2.5.1, with the integrated pathogenicity-prediction tools. The Alamut splice-site-prediction module includes the following methods: SpliceSiteFinder-like, MaxEntScan, MNSplicer, GeneSplicer, and Human Splicing Finder. Sequence alignment with SELENBP1 orthologs was done with the Clustal Omega (EMBL-EBI) webtool.
For frequency analysis, we used ExAC (URLs). We used the CADD tool to estimate the pathogenicity of mutations found in the ExAC browser. This tool prioritizes functional, deleterious, and pathogenic variants across many functional categories by using a CADD PHRED-like C score 59 .
Phylogenetic analysis of methanethiol oxidases and putative selenium-binding proteins. Evolutionary history was inferred through the neighbor-joining method. The two enzymes with proven MTO activity are indicated in red. Accession numbers are given in parentheses. The optimal tree with the sum of branch length = 10.21887791 is shown. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (500 replicates) is shown next to the branches for values > 60. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed with a Dayhoffmatrix-based method and are in units of the number of amino acid substitutions per site. The analysis involved 45 amino acid sequences. All ambiguous positions were removed for each sequence pair. There were a total of 564 positions in the final dataset. Evolutionary analyses were conducted in MEGA6 (ref. 52 ).
SELENBP1 mRNA tissue expression analysis. The expression profile of SELENBP1 was determined as previously described 60 . Primer sequences used to detect SELENBP1 mRNA expression can be found in Supplementary Table 2 .
Structural analysis. As a template to build a homology model of human SELENBP1 (40% identity), we used the structure of the hypothetical seleniumbinding protein from S. tokodaii (st0059, heterologously expressed in Escherichia coli), which was solved by X-ray crystallography and deposited in the PDB in 2007 (PDB 2ECE). This model was used to study the structural details of the p.Gly225Trp and p.His329Tyr alterations and was created and visualized with the WHAT IF and YASARA Twinset 61, 62 . The figures were rendered with PovRay (URLs).
Lentiviral complementation.
A Gateway-compatible expression vector for wild-type SELENBP1 without a stop codon was purchased from PlasmID/Harvard Medical School and recombined with the pLenti6.2V5-DEST destination vector (Invitrogen) with Gateway LR Clonase II Enzyme Mix (Invitrogen) according to the manufacturer's instructions. The resulting pLenti6.2-SELENBP1-V5 or the control construct pLenti6.2-AcGFP-V5 (Aequorea coerulescens green fluorescent protein) were used to produce viruses for fibroblast infection and selection of cells with stable expression, as previously described 63 .
Immunofluorescence microscopy. For immunofluorescence detection of V5-tagged SELENBP1, the stably transduced patient fibroblasts were grown on coverslips. The cells were fixed with 3.3% paraformaldehyde in cell-culture medium for 15 min, washed three times with PBS and permeabilized for 15 min with 0.5 Triton X-100 in PBS/10% FCS. The primary mouse antibody (Invitrogen anti-V5, 37-7500) was diluted 1:100 in PBS/10% FCS and incubated for 1 h. After extensive washing, the secondary antibody (goat-anti-mouse IgG Alexa Fluor 568, Invitrogen, A11004) was diluted 1:1,000 in PBS/10% FCS and incubated for 1 h. After being washed, the slides were mounted with ProLong Gold antifade with DAPI (Invitrogen). Image acquisition was performed with a Zeiss Observer Z1 instrument with LED illumination and appropriate emission filters.
MTO enzyme assay.
For MTO enzymatic activity measurements, plasma or cell homogenates were incubated in closed bottles, and the disappearance of added methanethiol was measured through headspace GC analysis. The use of new glassware proved essential for obtaining low and reproducible background measurements. To compare MTO activity in fibroblast and colon cell lines, we used 3-ml Exetainer vials (Labco Limited). Cell homogenates (400-700 µ l, equivalent to 0.75-1.85 mg protein) were transferred into the vials, and ZnSO 4 (0.2 mM final concentration) was added to trap H 2 S produced by MTO. This concentration was found not to inhibit the MTO enzymatic activity. After the bottles were closed, 12-25 µ l of a freshly prepared methanethiol stock solution (0.82 mM) was added by syringe, thus resulting in a 12-23 µ M methanethiol concentration in the liquid phase. Vials were horizontally shaken at 200 r.p.m. and 35 °C. For methanethiol analysis, 100-µ l gas samples were collected by syringe and subjected to GC analysis. Because of the reactivity of methanethiol, mainly oxidation into dimethyldisulfide, we always detected low levels of methanethiol disappearance in control bottles without added enzyme. These rates were subtracted from the experimental rates. For MTO activity measurements in erythrocytes and mouse tissue extracts, the standard assay was performed in 250-ml screw-cap serum bottles (neck size 28-mm ID). This setup allowed larger gas samples to be used for GC analysis with fewer effects of changing the gas volume and septum leakage. In addition, the background methanethiol disappearance was much lower. Bottles with 25 ml of PBS containing ZnSO 4 (0.2 mM) and BSA (0.3 mg/ml) were closed with rubber septa and incubated at 350 r.p.m. at 35 °C. Four nanomoles of methanethiol was added, thus resulting in approximately 50 nM in the liquid phase. For the determination of the reaction stoichiometry and the oxygen dependency, higher methanethiol concentrations were used (20-75 nmoles, thus resulting in 250-950 nM methanethiol in the liquid). After preincubation with methanethiol for 15-20 min, the MTO reaction was started by the addition of erythrocytes or tissue extracts, which were diluted in 1 ml PBS. Gas samples (1 ml) were collected every 1.5-4 min for GC analysis. The lower limit of detection for MTO activity in erythrocytes was 0.01 nmol µ l −1 h −1 , that in fibroblasts was 0.5 nmol mg protein −1 h −1 , and that in mouse tissue extracts was 1 nmol mg protein −1 h −1 .
To study the kinetics of MTO in erythrocytes and colon cells, the assay was scaled up to 500-ml serum bottles with 50 ml PBS. The amount of MTO added was adjusted to result in a reliable MT consumption rate over a period of ~10-20 min.
At the end of the incubations with fibroblasts, to release zinc-trapped H 2 S, HCl was added with a syringe to a final concentration of 0.1 M, and the bottles were shaken for 10 min at 25 °C to reach gas-liquid equilibration for H 2 S. The resulting H 2 S concentration was determined in the headspace by GC analysis. Total H 2 S was calculated by assuming a gas/liquid concentration ratio for H 2 S of 1:47, which was calculated from previously reported solubility data 64 . Addition of zinc traps the H 2 S that otherwise builds up over time and inhibits the MTO enzyme reaction.
The gas/liquid ratio for the concentration of methanethiol in PBS at 35 °C was determined at 1:5.5 and was calculated from the amount of MT that dissolved in the liquid after addition of a fixed amount of methanethiol to a closed 50-ml bottle that contained 10 ml of PBS. The dissolved amount was determined by comparing the headspace methanethiol concentration of the gas phase in this bottle with the gas-phase methanethiol concentration in an empty bottle (without PBS) that received the same amount of methanethiol. A slightly different ratio of 1:5 was obtained when PBS was used in 250-ml bottles to which BSA (0.3 mg ml −1 ) was also added. For sulfide, a gas/liquid ratio of 1:12.5 was obtained in these bottles. After acidification, the obtained value of 1:5.5 was much lower than expected at 35 °C (1:2) (ref. 64 ). We attributed the higher amount of sulfide dissolved to the presence of BSA, for which adsorption of sulfide has been suggested 65 .
The BRENDA database was accessed to search for enzymes with low K m values (URLs).
To determine DMS in mouse plasma, 200-µ l samples were introduced via a septum into a closed glass syringe that contained 3 ml of air and had been preincubated at 70 °C in a water bath. The samples were incubated for 5 min with intermittent shaking. At 70 °C, most of the DMS from the sample was in the gas phase. Subsequently, 2.6 ml of gas phase was transferred into a 3-ml syringe and analyzed by GC. From water samples with DMS, > 80% was recovered in this way. The DMS lower limit of detection was 1.5 nM. 
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